21st ECCMID / 27th ICC

21st ECCMID / 27th ICC
7-10.05.2011, Milan - Italy

Official symposia
Rare in the North, frequent in the South: infections from the Mediterranean Basin
* Brucellosis
* Cystic hydatidosis
* Visceral leishmaniasis
* Toscana virus infection
Risk factors other than neutropenia for developing infection in immunosuppressed patients
* Toll-like receptor polymorphisms and fungal infections
* Complement and fungal infections
* Mannose-binding lectin and bacterial infections in patients with haematological cancer
* Severe graft-versus-host disease (GVHD) and infection in allogeneic stem cell recipients
Infective endocarditis: lights & shadows
* The changing epidemiology
* Guidelines on antimicrobial prophylaxis: evidence and controversies
* Culture-negative endocarditis: a diagnostic conundrum
* When the surgeon is needed
Q fever: a major threat in Europe
arranged with the ESCMID Study Group for Coxiella, Anaplasma, Rickettsia and Bartonella (ESCAR)
* Q fever in the Netherlands: epidemiology of the largest ongoing European outbreak
* Q fever in animals: epidemiology, diseases in animals and zoonotic risk
* Q fever: prevention and treatment issues during an outbreak
* Coxiella burnetii: lessons from genomics
European preparedness and response to highly infectious diseases
* What will the 21st century outbreak look like?
* Networking approach in the face of highly infectious diseases
* Management of highly pathogenic infectious diseases in Europe – a EUNID recommendation
* The role of ECDC in preparedness and response to highly infectious diseases
Infection control methods for cancer patients undergoing treatment
* Prospective: logic and implementation over the years
* Practice and guidelines in Europe
* The base of evidence
* Infection control measures for prevention of fungal infections in neutropenic patients
How to decrease resistance in the ICU
arranged with the European Society of Intensive Care Medicine (ESICM)
* Predicting MDR pathogens: risk factors and laboratory approach
* The de-escalation approach
* The challenge of shortening therapy
* The reality of infection control in the ICU
Antimicrobial peptides – update for infectious disease physicians
arranged with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and ESCMID
* The human skin, AMPs, infection and inflammation
* Antimicrobial peptides in the lung
* Antimicrobial peptides in the intestinal tract
* Antimicrobial peptides and urogenital tract infection
New insights in the role of the commensal flora
* The role of the commensal intestinal flora in inflammatory bowel diseases
* Do nutrient-gut-microbiota interactions play a role in human obesity and 2 diabetes?
* The “Microflora Hypothesis” of allergic diseases
* The intestinal flora as reservoir of known and unknown resistance genes
Infection control without borders
* The EuRegio experience of successful cross-border infection control (NL-D)
* The WHO experience: worldwide “clean care is safer care”
* International transfer of patients and MDRO control
* What can we learn from each other in infection control – EU vs. USA experience?
The future of hospital antibiotic stewardship – what should we achieve by 2020?
* Computerised decision support systems
* Interactive E-learning
* Rapid DNA-based tests
* Biomarkers: anything beyond PCT?
Under your skin: skin manifestations of parasitic diseases
arranged with the ESCMID Study Group for Clinical Parasitology (ESGCP)
* Skin manifestations of parasitic diseases: what you should know, how to diagnose
* Photodynamic therapy in cutaneous leishmaniasis
* Toxocariasis in patients with skin disorders
* Maggot debridement therapy
Clinical problems from parasitology
* Severe malaria
* Cutaneous leishmaniasis
* Strongyloides hyperinfestation
* African trypanosomiasis
New models for microbiology lab services
* Challenges and opportunities for clinical microbiology
* Core labs and point-of-care microbiology labs
* Fully automated microbiology labs: an inevitable evolution?
* The evolving role of the clinical microbiologists
New aspects of antimicrobial treatment of anaerobic infections
arranged with the ESCMID Study Group for Antimicrobial Resistance in Anaerobic Bacteria (ESGARAB)
* Clinical failures in the antimicrobial treatment of anaerobic infections
* Antimicrobial resistance in Clostridium difficile
* Bacteroides, Prevotella and Porphyromonas are becoming more resistant to antimicrobial agents
* New approaches to treat anaerobic infections
Antimicrobial-resistant bacteria in food and potable water: a recipe for disaster?
arranged with the ESCMID Food- and Water-borne Infections Study Group (EFWISG)
* Antibiotic-resistant bacteria in food: from farm to fork
* Antibiotic-resistant bacteria in potable water: tapping into the problem
* Chewing it over: the clinical and public health relevance of antibiotic-resistant bacteria in food
* Reining in resistance: what role for organic farming methods?
Genetics and epidemiology of mobile resistance: mobilome & resistome
* SCCmec elements in staphylococci – origins, evolution and dissemination
* Mobile genetic elements behind resistance in streptococci
* Transposable elements in mobilisation and spread of resistance genes in Gram-negatives
* Resistance plasmid families in Enterobacteriaceae
Emergence of virulent and antibiotic-resistant bacterial forms in the marine environment: a public health concern
* Mobile genetic elements transferring virulence and antibiotic resistance genes among marine bacteria
* Pathogenic effects of marine Vibrio strains on human cells
* Fish farms as a reservoir of antibiotic-resistant bacteria potentially pathogenic to humans
* Monitoring and modelling the microbiological quality of water and shellfish
Surveillance of resistance in M. tuberculosis and potential impact of epidemiological cut-off values
arranged with the ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST)
* The critical concentration is important
* The critical proportion is important
* Molecular tools for surveillance of resistance in TB
* Epidemiological cut-off values in M. tuberculosis – potential impact on breakpoints
Antibiotic combination interactions
* When two is better than one
* When no clues indicate amelioration by combination therapy
* Quantitative assessment and mathematical modelling
* Antibiotic combination in the critical patient
The role of PK-PD in the treatment of severe infections
arranged with the ISC Working Group on Pharmacokinetics/Pharmacodynamics
* MRSA, enterococci, P. aeruginosa and Acinetobacter sp.: where are we going with resistance patterns?
* PK-PD differences among old and new glycopeptides and new anti Gram-positive compounds
* PK-PD and anti Gram-negative compounds: which is the exact role?
* Do we need new compounds?
The role of PK-PD for choosing antifungal drugs
arranged with the ISC Working Group on Pharmacokinetics/Pharmacodynamics
* In vitro antifungal activity: importance and limits
* PK-PD of antifungal drugs: do we have sufficient knowledge?
* Therapeutic drug monitoring and antifungal drugs: where are we today?
* Combination therapy: do PK-PD concepts apply?
New diagnostic methods for invasive fungal infections
* Non-culture-based diagnosis of invasive aspergillosis
* Latest developments in molecular detection of outbreaks
* Rapid detection of Candida species and resistance from blood cultures
* Old pathogens, new species: the role of the new taxonomy
Late presenters in Europe
* Epidemiology of late presenters in Europe (Euro-CDC)
* Advances in the microbiological diagnosis of opportunistic infections in AIDS patients
* When to start anti-retroviral therapy in patients with opportunistic infections
* Risk factors, immunopathology and management of IRIS
Pathogenesis of Chlamydia infections
* Adhesion: a crucial step for chlamydial virulence
* Subversion of the structure and function of the Golgi of the host cell by Chlamydia trachomatis
* Pathogenesis and evolution of Chlamydia: lessons from genomics of novel chlamydiae
* Immunogenetics: why do not all women get infertile following chlamydial infection?
Imaging infection
* Imaging human infections (Ultrasound, CT-scan, MRI, PET)
* Imaging microbes in vivo
* Dynamic imaging (bioluminescence, two-photon imaging)
* Ultraresolutive imaging (FRAP, STORM, Electron microscopy, Tomography)
Genetic predisposition and the outcome of infection: time to include genetic polymorphisms in routine diagnostic work-up?
* Host genetics, predisposition and outcome in meningococcal disease
* Genetics of susceptibility to Plasmodium falciparum
* Genetic dissection of host resistance to Mycobacterium tuberculosis
* Helicobacter pylori infection, host genetics and gastric cancer
Clinical Grand Rounds
* tbd
Infectious disease with liver involvement – an update
arranged with the Asociación Panamericana de Infectologia
* Hepatitis B treatment. Current guidelines in Latin America and variability in access to treatment
* Update on leptospirosis: how to diagnose and therapeutic options
* Hepatic dysfunction in dengue, yellow fever and malaria
* Diagnosis and treatment of liver abscesses
Controlling MRSA
arranged with the ISC Working Group on MRSA and the Scottish Microbiology Association (SMA)
* Routine admission screening or risk assessment?
* MRSA carriage – methods of detection
* Measures to be taken: hand hygiene, isolation, hospital cleaning
* Is it cost-effective?
Opportunistic infections in solid organ transplant recipients
* Human Cytomegalorvirus (HCMV) infection in transplant recipients
* Respiratory viruses in transplant recipients
* Polyomavirus infection in kidney transplant recipients
* Epstein-Barr virus (EBV) adoptive immunotherapy in transplant recipients
Next generation sequencing and clinical microbiology
* Next generation DNA sequencing techniques
* Use of next generation sequencing in microbiological research (pathogenesis)
* Use of next generation sequencing in epidemiology
* Possible use of next generation sequencing in routine clinical microbiology
Bridging the gap of innovation – what we all could do
arranged with the ESCMID PK/PD of Anti-Infectives Study Group (EPASG) and the ISC Working Group: Antimicrobials of the Future
* Antibacterial pipelines – what to expect in the future
* Political processes for the global need for effective antibiotics – moving towards concerted action
* New ways of using old and coming antibiotics
* Improving usage by guidelines – the European experience
Milestones in antimicrobial chemotherapy during the past 50 years!
* Penicillins
* Cephalosporins
* Aminoglycosides
* From sulphonamides to fluoroquinolones
Resistant superbugs: a comparative analysis of Asia versus Europe
* In vitro resistance and in vivo efficacy
* MRSA, VISA, and VRSA
* ESBLs & carbapenemases
* Quinolone resistance in Gram-negative bacilli
Antimicrobial stewardship works - why isn't it widely practiced?
* Antimicrobial stewardship: Where we are? World initiatives inventory
* Successful strategies and campaigns to improve outpatient antibiotic usage
* The antibiotic paradox; are new antibiotics the answer?
* Why is stewardship not widely practiced?
ISF Symposium and Presentation of International Sepsis Forum Award
* Pathophysiology: damage associated molecular patterns
* Diagnosis of sepsis: microbes vs biomarkers?
* The current status of MD2-TLR4 inhibitors in the treatment of sepsis
* Is there a rationale to use immunostimulation to counteract the altered immune status of sepsis and SIRS patients?
Enterococci – where are we now?
* Current epidemiology of vancomycin-resistant enterococci in Europe
* What do we learn about enterococci from genomic studies?
Pro vs. Con: guideline vs. clinical practice-driven strategies in treating severe infectious diseases
* Guidelines are essential for treatment and diagnosis
* Nothing can replace clinical judgement
Infections and human genetic susceptibility
* Where are we?
* Where are we going?
Quality control: is it needed?
* Quality control in molecular diagnostics
* Quality control in MALDI-TOF
Hospitalised CAP – penicillin/doxy vs. FQ or Ceph3/macrolide?
* Penicillin + [doxy or macrolide]
* Pro FQ or Ceph3/macrolide?
Vancomycin and staphylococci – is it as bad as they say?
arranged with the European Committee on Antimicrobial Susceptibility Testing (EUCAST)
* Pro
* Con
Antifungal drugs make me mad: candins or azoles
* Candins
* Azoles
Recent advances in the pathogenesis of Cytomegalovirus (CMV) and Epstein-Barr virus (EBV)
* Recent advances in the pathogenesis of CMV infection
* Recent advances in the pathogenesis of EBV infection
Are probiotics growth promoters on humans?
* No
* Yes
RNAi and viral infections
* Whole genome RNAi screen and novel antiviral targets
* RNAi as a therapeutic approach against viruses
Viral resistance testing – where are we?
* European HIV Drug Resistance Guidelines – update
* Hepatitis B viral resistance testing
Antifungal management strategies
* The ICU patient
* The haematological patient
Do you know the concept of anti-anaerobic quinolones?
arranged with the Japanese Society of Chemotherapy
* Overview on anaerobic fluoroquinolones
* Clinical significance of anti-anaerobic quinolones in VAT and VAP
Clinical management of urinary tract infections
* An update of complicated urinary tract infections
* How to treat acute pyelonephritis
Eradication of malaria
* Global perspectives and policies
* Vaccines
New molecular diagnostics for parasitic diseases
* Molecular versus microscopic diagnosis of faecal parasites; the pros and cons.
* Molecular diagnosis of blood and tissue protozoa; time to discard the microscope
The year in clinical microbiology
The year in infectious diseases
The year in infection control


www.eccmid-icc2011.org/eccmid-icc2011